{"url_path":"/sec/eton/8-k/2026-04-27/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-04-27","source_url":"https://www.sec.gov/Archives/edgar/data/1710340/0001437749-26-013369-index.html","accession_number":"0001437749-26-013369","cik":"0001710340","ticker":"ETON","issuer_name":"Eton Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1710340/0001437749-26-013369-index.html","primary_entity_key":"0001710340","primary_entity_name":"Eton Pharmaceuticals, Inc."},"word_count":67,"has_tables":true,"body_markdown":"**Item 8.01: Other Events**\n\n \n\nOn April 27, 2026, Eton Pharmaceuticals, Inc. (the “Company”) issued a press release announcing a pilot study underway for product candidate ET-700, the Company's extended-release formulation of zinc acetate, which will be compared to Galzin® and a placebo for the treatment of Wilson disease. \n\n \n\nA copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.\n\n \n\n \n\n2"}